American Journal of Cardiovascular Drugs

, Volume 13, Issue 6, pp 385–398 | Cite as

HMG-CoA Reductase Inhibitors in Chronic Kidney Disease

  • A. Olyaei
  • J. L. Steffl
  • J. MacLaughlan
  • M. Trabolsi
  • S. P. Quadri
  • I. Abbasi
  • E. Lerma
Review Article


The incidence of chronic kidney disease (CKD) is on the rise in the USA. Cardiovascular events are the leading cause of death in this patient population, therefore reducing the risk of these events has become a major focus. The aim of this review is to assess current literature on the use of statins in CKD and end-stage renal disease. Cholesterol reduction is important in preventing the development and progression of coronary heart disease and its negative effects. Statins have been widely studied and proven to reduce cardiovascular risk in the general population. The information gained from trials has been extrapolated to special populations, including CKD, despite these patients often being excluded. However, recent studies have begun to focus on CKD, hemodialysis, and transplant patients and the use of cholesterol-lowering agents and the potential association with decreased cardiovascular events. In addition, due to the unique pharmacokinetic and pharmacodynamic changes that occur in these patients, choosing the appropriate cholesterol-lowering agent becomes important for both safety and efficacy. The complexity of CKD patients is an important consideration when choosing cholesterol-lowering medication. Patients with CKD are often on medications that may interact with many of the cholesterol-lowering agents. Ensuring drug interactions are minimized is essential to the prevention of adverse events from the medications.


  1. 1.
    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143–421.Google Scholar
  2. 2.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486–97.Google Scholar
  3. 3.
    US Renal Data System. USRDS 2006 annual data report: atlas of end-stage renal disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006.Google Scholar
  4. 4.
    Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003;41(4 Suppl 3):I-91.Google Scholar
  5. 5.
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.PubMedCrossRefGoogle Scholar
  6. 6.
    Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351(13):1285–95.PubMedCrossRefGoogle Scholar
  7. 7.
    Fellström B, Holdaas H, Jardine AG, et al. Cardiovascular disease in patients with renal disease: the role of statins. Curr Med Res Opin. 2009;25(1):271–85.PubMedCrossRefGoogle Scholar
  8. 8.
    Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–48.PubMedCrossRefGoogle Scholar
  9. 9.
    Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;14:1395–407.CrossRefGoogle Scholar
  10. 10.
    Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–92.PubMedCrossRefGoogle Scholar
  11. 11.
    Kasiske BL, O’Donnell MP, Garvis WJ, Keane WF. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res. 1988;62(2):367–74.PubMedCrossRefGoogle Scholar
  12. 12.
    Kasiske BL, Wanner C, O’Neill WC. An assessment of statin safety by nephrologists. Am J Cardiol. 2006;97(8A):82C–5C.Google Scholar
  13. 13.
    US Department of Health and Human Services. US FDA. FDA: limit use of 80 mg simvastatin. 2011 Jun 8 [Consumer update]. (Accessed)
  14. 14.
    Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol. 2011;57(14):1535–45.PubMedCrossRefGoogle Scholar
  15. 15.
    Greving JP, Visseren FL, de Wit GA, Algra A. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ. 2011;342:d1672.PubMedCrossRefGoogle Scholar
  16. 16.
    Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis. 2009;203(2):325–30.PubMedCrossRefGoogle Scholar
  17. 17.
    Sadowitz B, Maier KG, Gahtan V. Basic science review: statin therapy—part I: the pleiotropic effects of statins in cardiovascular disease. Vasc Endovascular Surg. 2010;44(4):241–51.PubMedCrossRefGoogle Scholar
  18. 18.
    Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004;109(23 Suppl 1):III50–7.Google Scholar
  19. 19.
    Munar MY, Singh H. Drug dosing adjustments in patients with chronic kidney disease. Am Fam Phys. 2007;75(10):1487–96.Google Scholar
  20. 20.
    Coresh J, Longenecker JC, Miller ER III, Young HJ, Klag MJ. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol. 1998;9(12 Suppl):S24–30.PubMedGoogle Scholar
  21. 21.
    Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291(4):451–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Radhakrishnan J, Appel AS, Valeri A, Appel GB. The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis. 1993;22(1):135–42.PubMedGoogle Scholar
  23. 23.
    Kronenberg F, Lingenhel A, Lhotta K, et al. Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: impact on lipid-lowering therapy? Kidney Int. 2004;66(1):348–54.PubMedCrossRefGoogle Scholar
  24. 24.
    Rayner HC, Ross-Gilbertson VL, Walls J. The role of lipids in the pathogenesis of glomerulosclerosis in the rat following subtotal nephrectomy. Eur J Clin Invest. 1990;20(1):97–104.PubMedCrossRefGoogle Scholar
  25. 25.
    Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41(3):565–70.PubMedCrossRefGoogle Scholar
  26. 26.
    Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110(12):1557–63.PubMedCrossRefGoogle Scholar
  27. 27.
    Shepherd J, Kastelein JJ, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2(6):1131–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb. 2011;18(11):1018–28.PubMedCrossRefGoogle Scholar
  29. 29.
    Lee TM, Su SF, Tsai CH. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension. 2002;40(1):67–73.PubMedCrossRefGoogle Scholar
  30. 30.
    Molnar AO, Coca SG, Devereaux PJ, et al. Statin use associates with a lower incidence of acute kidney injury after major elective surgery. J Am Soc Nephrol. 2011;22(5):939–46.PubMedCrossRefGoogle Scholar
  31. 31.
    Ruggenenti P, Perna A, Tonelli M, et al. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin–angiotensin system blockade: the ESPLANADE trial. Clin J Am Soc Nephrol. 2010;5(11):1928–38.PubMedCrossRefGoogle Scholar
  32. 32.
    Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009;(2):CD007784.Google Scholar
  33. 33.
    Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157(4):263–75.PubMedCrossRefGoogle Scholar
  34. 34.
    Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361(9374):2024–31.PubMedCrossRefGoogle Scholar
  35. 35.
    Younas N, Wu CM, Shapiro R, et al. HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: statins not associated with improved patient or graft survival. BMC Nephrol. 2010;11:5.PubMedCrossRefGoogle Scholar
  36. 36.
    Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565–81.PubMedCrossRefGoogle Scholar
  37. 37.
    Mammen AL, Amato AA. Statin myopathy: a review of recent progress. Curr Opin Rheumatol. 2010;22(6):644-50.Google Scholar
  38. 38.
    Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf. 2010;33(3):171–87.PubMedCrossRefGoogle Scholar
  39. 39.
    Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006;16(12):873–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol. 2010;105(5):978–80.PubMedCrossRefGoogle Scholar
  41. 41.
    McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97(8A):89C–94C.Google Scholar
  42. 42.
    Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;36(2):288–95.PubMedCrossRefGoogle Scholar
  43. 43.
    Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother. 2001;35(9):1096–107.PubMedCrossRefGoogle Scholar
  44. 44.
    Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585–90.PubMedCrossRefGoogle Scholar
  45. 45.
    Olyaei AJ, Bennett WM. Drug dosing in the elderly patients with chronic kidney disease. Clin Geriatr Med. 2009;25(3):459–527.PubMedCrossRefGoogle Scholar
  46. 46.
    Sawara Y, Takei T, Uchida K, et al. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease. Intern Med. 2008;47(17):1505–10.PubMedCrossRefGoogle Scholar
  47. 47.
    Isbel NM, Haluska B, Johnson DW, Beller E, Hawley C, Marwick TH. Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. Am Heart J. 2006;151(3):745–53.PubMedCrossRefGoogle Scholar
  48. 48.
    Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20(4):614–20.PubMedCrossRefGoogle Scholar
  49. 49.
    Kendrick J, Shlipak MG, Targher G, Cook T, Lindenfeld J, Chonchol M. Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. Am J Kidney Dis. 2010;55(1):42–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Nakamura H, Mizuno K, Ohashi Y, Yoshida T, Hirao K, Uchida Y. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis. 2009;206(2):512–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368(9542):1155–63.PubMedCrossRefGoogle Scholar
  52. 52.
    Holme I, Fayyad R, Faergeman O, et al. Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial. J Intern Med. 2010;267(6):567–75.PubMedCrossRefGoogle Scholar
  53. 53.
    Baigent C, Landray M, Leaper C, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005;45(3):473–84.PubMedCrossRefGoogle Scholar
  54. 54.
    Bianchi S, Bigazzi R, Campese VM. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. Am J Kidney Dis. 2010;55(4):671–81.PubMedCrossRefGoogle Scholar
  55. 55.
    Shibui T, Nakagomi A, Kusama Y, Atarashi H, Mizuno K. Impact of statin therapy on renal function and long-term prognosis in acute coronary syndrome patients with chronic kidney disease. Int Heart J. 2010;51(5):312–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Rashidi A, Ghanbarian A, Azizi F, Adler DS. Is chronic kidney disease comparable to diabetes as a coronary artery disease risk factor? South Med J. 2007;100(1):20–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Sciahbasi A, Arcieri R, Quarto M, et al. Impact of chronic aspirin and statin therapy on presentation of patients with acute myocardial infarction and impaired renal function. Prev Cardiol. 2010;13(1):18–22.PubMedCrossRefGoogle Scholar
  58. 58.
    Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis. 2009;53(5):741–50.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • A. Olyaei
    • 1
  • J. L. Steffl
    • 1
  • J. MacLaughlan
    • 1
  • M. Trabolsi
    • 2
  • S. P. Quadri
    • 2
  • I. Abbasi
    • 3
  • E. Lerma
    • 4
  1. 1.Division of Nephrology and HypertensionOregon State University and Oregon Health and Sciences UniversityPortlandUSA
  2. 2.University of Illinois at Chicago/Advocate Christ Medical CenterInternal Medicine Residency ProgramOak LawnUSA
  3. 3.University of Illinois at Chicago/School of Public HealthChicagoUSA
  4. 4.Division of Nephrology, Department of MedicineUniversity of Illinois at Chicago College of Medicine/Advocate Christ Medical Center Associates in NephrologyChicagoUSA

Personalised recommendations